Recombinant Human Interleukin-1 Receptor Antagonist, Anakinra, to Prevent Post-Infarction Remodeling: the Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART).
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2014
At a glance
- Drugs Anakinra (Primary)
- Indications Heart failure; Myocardial infarction
- Focus Therapeutic Use
- Acronyms VCU-ART
- 10 Jun 2017 Biomarkers information updated
- 15 May 2010 Results have been published (American Journal of Cardiology 105: 1371-1377.e1, No. 10, 15 May 2010).
- 16 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology.